Phase I clinical trial of recombinant human tumor necrosis factor

A phase I and pharmacokinetic study of recombinant tumor necrosis factor (rH-TNF Asahi) was carried out in 29 patients, who received a total of 72 courses with doses ranging from 1 to 48 X 10(4) units/m2. Drug was given as 1-h i.v. infusions. Acute toxicities, taking the form of fever, chills, tachy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 1987-10, Vol.20 (2), p.137-144
Hauptverfasser:	CREAVEN, P. J, PLAGER, J. E, DUPERE, S, HUBEN, R. P, TAKITA, H, MITTELMAN, A, PROEFROCK, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biological and medical sciences Drug Evaluation Female Humans Hypotension - chemically induced Liver - drug effects Liver - enzymology Male Medical sciences Middle Aged Neoplasms - drug therapy Neoplasms - metabolism Other treatments Recombinant Proteins Treatment. General aspects Tumor Necrosis Factor-alpha - adverse effects Tumor Necrosis Factor-alpha - pharmacokinetics Tumor Necrosis Factor-alpha - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!